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A recent phase 1 trial of the fatty acid amide hydrolase (FAAH) inhibitor BIA 10-2474 led to the
death of one volunteer and produced mild-to-severe neurological symptoms in four others.
Although the cause of the clinical neurotoxicity is unknown, it has been postulated, given the
clinical safety profile of other tested FAAH inhibitors, that off-target activities of BIA 10-2474
may have played a role. Here we use activity-based proteomic methods to determine the protein
interaction landscape of BIA 10-2474 in human cells and tissues. This analysis revealed that
the drug inhibits several lipases that are not targeted by PF04457845, a highly selective and
clinically tested FAAH inhibitor. BIA 10-2474, but not PF04457845, produced substantial
alterations in lipid networks in human cortical neurons, suggesting that promiscuous lipase
inhibitors have the potential to cause metabolic dysregulation in the nervous system.
I
n January 2016, a first-in-human study of the
fatty acid amide hydrolase (FAAH) inhibitor
BIA 10-2474 led to the death of one volunteer
and the hospitalization of four others (1–4).
All patients manifested mild-to-severe neu-
rological symptoms (3). FAAH is a membrane-
bound serine hydrolase that degrades the
endocannabinoid anandamide and related ami-
dated lipids (5–8). Three explanations for the
clinical neurotoxicity of BIA 10-2474 have been
proposed: (i) Errors may have occurred in the
clinical trial itself, either in the manufacturing
or handling of the compound or in the conduct
of the trial; (ii) through its inhibitory effects
on FAAH, BIA 10-2474 may have produced
high levels of long-chain fatty acid amides (e.g.,
anandamide) and their oxygenated metabolites,
which could potentially overstimulate cannabi-
noid type 1 (CB1) receptors (8), transient receptor
potential vanilloid 1 (TRPV1) ion channels (9), and/
or N-methyl-D-aspartate (NMDA) receptors (10); or
(iii) BIA 10-2474 and/or its metabolites might
have off-target activities. The first hypothesis was
dismissed by the French authorities (4). The
second hypothesis is considered unlikely because
other FAAH inhibitors, such as PF04457845,
have exhibited favorable safety profiles in
phase 1 and 2 clinical trials (11, 12). The third
hypothesis has not been directly evaluated,
because little or no information is available
regarding the protein interaction profile of
BIA 10-2474 (1).
BIA 10-2474 (Fig. 1A) contains an electrophilic
imidazole urea that may react with the nucleo-
philic serine of FAAH and other serine hydro-
lases to form covalent and irreversible adducts.
We predicted that the serine hydrolase targets
of BIA 10-2474 could be identified by using chem-
ical proteomic methods (13–15); this would allow
us to compare its selectivity profile to that of
PF04457845 (Fig. 1A), a FAAH inhibitor that
progressed to phase 2 trials without serious
adverse events (11, 12, 16). We first synthesized
BIA 10-2474 and BIA 10-2639, a confirmed me-
tabolite in which the N-oxide of BIA 10-2474 has
been reduced to a pyridine (4) (Fig. 1A), in two
independent labs and confirmed their structures
by 1H– and 13C–nuclear magnetic resonance
(NMR) and high-resolution mass spectrometry
(17). Both independently generated sets of com-
pounds displayed equivalent activities in the sub-
sequently described biological assays.
Our initial experiments performed with sub-
strate hydrolysis assays revealed that BIA 10-2474
showed weak in vitro inhibitory activity against
human and rat FAAH, displaying median inhib-
itory concentration (IC50) values ≥1 mM (Fig. 1B,
fig. S1, and table S1). Consistent with previous
reports (16), PF04457845 potently inhibited
FAAH with IC50 values of ~1 to 10 nM (Fig. 1B
and table S1). By contrast, BIA 10-2474 exhibited
greatly improved potency in cellular assays (in situ),
blocking human FAAH activity in transfected
HEK293T (human embryonic kidney 293T) cells
with IC50 values of 0.05 to 0.07 mM (Fig. 1B). BIA
10-2474 and PF04457845 did not interact with
other proteins of the endocannabinoid system
or with the endocannabinoid-binding transient
receptor potential (TRP) ion channels (tables S2
and S3).
We also created alkynylated analogs of BIA 10-
2474—AJ167, AJ179, and AJ198—and found that
two of these compounds (AJ179 and AJ198) labeled
mouse and human FAAH in brain lysates, as
detected by coupling to azide fluorescent reporter
groups via copper(I)-catalyzed azide-alkyne cyclo-
addition (“click”) chemistry (fig. S2) (18). This
finding, coupled with the time-dependent inhi-
bition of FAAH displayed by BIA 10-2474 (table
S1), provides strong evidence that BIA 10-2474
and related imidazole ureas exhibit an irreversible
mode of action.
To investigate the serine hydrolase interaction
landscape of BIA 10-2474, we used activity-based
protein profiling (ABPP), a chemical proteomic
method that uses active site–directed chemical
probes [e.g., fluorophosphonates (FPs) or b-lactones
for serine hydrolases] to assess the functional
state of entire enzyme classes directly in native
biological systems (13–15). When coupled to
fluorescent reporter groups, ABPP probes enable
visualization of enzyme activities in complex
proteomes by SDS–polyacrylamide gel electro-
phoresis (SDS-PAGE) and in-gel fluorescence
scanning. When coupled to a biotin reporter
group, ABPP probes enable affinity enrichment
and identification of enzyme activities by mass
spectrometry (MS)–based proteomics. In both
formats, ABPP serves as a versatile method to
assess target engagement and proteome-wide
selectivity for small-molecule inhibitors. Gel-
based ABPP with a fluorescent FP probe (FP-
TAMRA) confirmed the relative in vitro and in
situ potencies of BIA 10-2474 and PF04457845
for human FAAH in transfected HEK293T cell
preparations (Fig. 1C). The reason for the increased
cellular activity of BIA 10-2474 is unclear but could
reflect cellular accumulation of the compound,
which has been observed for other types of en-
zyme inhibitors (19).
Initial ABPP studies were performed in the
human colon carcinoma cell line SW620, which
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expresses a wide diversity of endogenous serine
hydrolase activities, including FAAH and FAAH2.
Isotopically heavy and light amino acid–labeled
SW620 cells were treated with dimethyl sulfoxide
(DMSO) or drug (BIA 10-2474 or PF04457845;
0.2 or 10 mM each for 4 hours, or 50 mM each for
24 hours) and then lysed and treated with a
biotinylated FP probe. The samples were then
combined and subjected to streptavidin enrich-
ment and quantitative liquid chromatography
(LC)–MS analysis, in which proteins displaying
heavy:light ratios of >2.0 were designated as drug-
inhibited targets. We focused on human cell
studies and tested a broad range of inhibitor
concentrations because the deleterious neuro-
logical effects of BIA 10-2474 were observed in
humans, but not other mammals, and occurred
at drug doses that were 10 to 50 times higher
than that required for blockade of FAAH activity
in the clinical trial participants (4).
Our MS-based ABPP studies confirmed that
both BIA 10-2474 and PF04457845 fully engaged
human FAAH at all tested concentrations (0.2,
10, and 50 mM) (Fig. 2, A and B, and fig. S3).
Both drugs showed good selectivity for FAAH at
the lowest concentration tested (0.2 mM; fig. S3).
PF04457845 maintained this selectivity profile
at higher concentrations, displaying only a single
major off-target—the homologous enzyme FAAH2—
among ~60 quantified serine hydrolases, consistent
with previous studies (16). By contrast, BIA 10-2474
and its metabolite BIA 10-2639 exhibited numer-
ous off-targets across the tested drug concentra-
tion range, including FAAH2 and several lipid
hydrolases, such as ABHD6, ABHD11, LIPE, and
PNPLA6, and xenobiotic drug-metabolizing en-
zymes CES1, CES2, and CES3 (Fig. 2, A and B).
Some of these off-targets, such as ABHD6 and
CES2, were almost completely inhibited (>90%)
at both 10 and 50 mM concentrations of BIA
10-2474.
Representative off-targets of BIA 10-2474 were
recombinantly expressed in HEK293T cells and
verified to engage BIA 10-2474 by gel-based ABPP
(Fig. 2C). These experiments also confirmed the
relative potency of off-targets mapped by MS-
based ABPP, with BIA 10-2474 exhibiting greater
inhibitory activity against ABHD6 and CES2
compared to PNPLA6. By contrast, none of the
recombinantly expressed enzymes were inhibited
by PF04457845 except FAAH2 (Fig. 2C).
Our chemical proteomic data, taken together,
demonstrated that both BIA 10-2474 and its
major metabolite BIA 10-2639 cross-react with
several human serine hydrolases that do not
interact with PF04457845 ( T1Table 1 and table S4).
One possible contributing factor to this broader
interaction profile is the greater intrinsic reac-
tivity of BIA 10-2474 compared to PF04457845,
which is reflected in their respective rates of
methanolysis (fig. S4). We also note that human
CES2 and ABHD6 were both more potently in-
hibited by BIA 10-2474 and BIA 10-2639 com-
pared to the mouse orthologs of these enzymes
(table S2), indicating the potential for species
differences in the off-target–mediated activities
of these compounds.
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Fig. 1. Comparison of human FAAH inhibition by BIA 10-2474, BIA 10-2639, and PF04457845.
(A) The structures of BIA 10-2474, the metabolite BIA 10-2639, and PF04457845. (B) Inhibition of
human FAAH in HEK293T cell lysates (in vitro) or intact cells (in situ) as measured with an
anandamide substrate hydrolysis assay. (C) In vitro and in situ inhibition of human FAAH as
measured by competitive gel-based ABPP. Top: HEK293Tcell lysates (in vitro) or intact cells (in situ)
recombinantly expressing human FAAH were pretreated with different amounts of compound or
DMSO (in vitro: 30 min, 37°C; in situ: 4 hours, 37°C). FAAH activity was measured by reactivity
with the serine hydrolase–directed probe FP-TAMRA and visualization of signals by gel-based ABPP.
Mock indicates control cells transfected with empty vector. Bottom: Corresponding IC50 curves for
gel-based ABPP data shown above. N = 3 independent experiments per group.
Table 1. In vitro and in situ inhibitory potencies of BIA 10-2474, BIA 10-2639, and PF04457845
against FAAH and representative off-targets. Measurements were made by gel-based ABPP of
HEK293T cells recombinantly expressing the indicated human serine hydrolases. Data represent
inhibitor treatment of cells for 4 hours with the exception of PNPLA6, where data represent inhibitor
treatment of cells for 24 hours. Data represent average values from three independent experiments per
group. See table S4 for error measurements related to IC50 values. ND, not determined.
IC50 (mM)
Enzyme Treatment BIA 10-2474 BIA 10-2639 PF04457845
FAAH In vitro 7.5 4.1 0.004
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. .
FAAH In situ (4 hours) 0.049 0.049 0.011
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. .
FAAH2 In situ (4 hours) 0.40 0.10 0.59
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. .
ABHD6 In situ (4 hours) 0.081 0.079 >10
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. .
CES2 In situ (4 hours) 2.0 0.63 >10
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. .
ABHD11 In situ (4 hours) >10 2.3 >10
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. .
PNPLA6 In situ (24 hours) 11 ND >50
.. .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... .. ... ... .. ... ... .. ... ... .. .
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Many of the off-targets of BIA 10-2474 are
involved in cellular lipid metabolism (20, 21),
and most (with the exception of FAAH2) show
substantial expression in human brain tissue (fig.
S5). Although the poor in vitro activity displayed
by BIA 10-2474 limited our ability to identify off-
targets in brain tissue lysates, we could confirm
cross-reactivity of this drug with both FAAH and
ABHD6 in human frontal cortex proteome (post-
mortem samples acquired from three male donors
who were 49, 50, and 80 years of age and who
were not associated with the BIA 10-2474 trial)
(fig. S6). We also observed several of the off-targets
of BIA 10-2474 by ABPP of human cortical neu-
rons derived from induced pluripotent stem
cells (fig. S7).
We next tested whether prolonged exposure
to BIA 10-2474 altered lipid metabolism in hu-
man cortical neurons. We performed targeted
lipidomic analysis of human cortical neuron
cultures treated with vehicle (DMSO) or BIA 10-
2474 (50 mM) at a concentration that was ~20
times greater than the maximum concentration
(Cmax) observed in the human clinical trial (22). In
total, the amounts of 161 lipid species were
quantified, of which 54 showed a fold change
of ≥1.20 or ≤0.80 when using a Benjamini-
Hochberg false-discovery rate ≤25% (Fig. 3A
and table S5). The lipids affected by BIA 10-2474
included FAAH substrates (N-acylethanolamines),
as well as several other lipid classes, including
triglycerides, monoacylglycerols, (lyso)phospha-
tidylcholines, free fatty acids, and plasmalogens.
By contrast, treatment of human cortical neuron
cultures with PF04457845 (1 mM), which was
also tested at a concentration that was 20 times
greater than the clinical Cmax for the drug (11),
produced a more restricted profile of lipid changes,
predominantly corresponding to the expected
elevations of N-acylethanolamines (Fig. 3B).
Here we have shown that BIA 10-2474 acts as
an irreversible inhibitor of FAAH that displays
greater cross-reactivity with human serine hydro-
lases than the clinically tested FAAH inhibitor
PF04457845. Many of the off-targets of BIA 10-2474
are lipolytic enzymes, raising the possibility that
disruption of cellular lipid networks may have
contributed to the compound’s neurotoxicity. No-
tably, disruption of neuronal lipid metabolism
by inhibition of PNPLA6, one of the off-target pro-
teins of BIA 10-2474 identified in this study, has
previously been linked to organophosphate-based
neurotoxicity in humans (21, 23–25), and recessive
loss-of-function mutations in the PNPLA6 gene
are responsible for a broad spectrum of neuro-
degenerative disorders (26, 27).
Although our data provide information about
the selectivity of BIA 10-2474, they do not allow
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Fig. 3. BIA 10-2474, but not PF04457845,
causes substantial alterations in lipid
metabolism in human cortical neurons.
(A and B) Cortical neurons were treated with
DMSO or BIA 10-2474 (50 mM) (A) or with
DMSO or PF04457845 (1 mM) (B) and analyzed
by MS-based lipidomics after 48 hours. The
x axis shows the fold change of lipid species in
the inhibitor-treated versus DMSO-treated
cells. Lipidomic data are presented as a volcano
plot, and lipids with a fold-change threshold
of ≥1.20 or ≤0.80 and a Benjamini-Hochberg
false-discovery rate (FDR) ≤25% are repre-
sented by colored circles indicating lipid class.
Data represent average values from at least two
independent experiments.
Fig. 2. Quantitative proteomic analysis of serine hydrolase targets of FAAH inhibitors in
human cells. (A and B) MS-based ABPP of serine hydrolase activities in SW620 cells treated with
DMSO or FAAH inhibitor. Shown in (A) are BIA 10-2474, BIA 10-2639, and PF04457845 (10 mM,
4 hours, 37°C). Shown in (B) are BIA 10-2474 and PF04457845 (50 mM, 24 hours, 37°C). Data are
expressed as median stable isotope labeling by amino acids in cell culture (SILAC) ratio values for all
isotopic peptide pairs quantified per protein from two biological replicates. (C) Confirmation of
representative off-targets of BIA 10-2474 by gel-based ABPP of recombinantly expressed enzymes in
HEK293T cells.
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us to conclude that inhibition of one or more of
the identified off-target proteins is responsible
for the clinical neurotoxicity caused by this drug.
Nor can we exclude the possibility that nonco-
valent interactions of BIA 10-2474 or its metabo-
lites with other proteins might have contributed
to the reported clinical effects (28). Regardless,
our study highlights the general utility of ABPP
as a versatile chemical proteomic method to as-
sess on-target engagement and off-target activity of
covalent drugs to guide therapeutic development.
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